Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRID: GM-CSF to Decrease ICU Acquired Infections in Sepsis-induced ImmunoDepression
NCT02361528Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2015
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of sargramostim in sepsis, septic shock, sponsored by Hospices Civils de Lyon. Started Sep 2015; status: completed.
02
Drugs
sargramostim
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT02361528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361528.